Pneumonia is an inflammatory disease in the lungs and can be caused by a variety of pathogens, of which bacterial infections are more common. In the treatment of pneumonia, the rational choice of anti-bacterial drugs is crucial and has a direct impact on treatment effectiveness and patient prognosis.
I. Selection by pathogen type
The determination of the pathogen of pneumonia is key to the precise selection of antibacterial drugs. For community access to pneumonia (CAP), common pathogens include streptococcus pneumonia, haemophilus influenzae, catamola, etc. Among them, pneumocococcus, where penicillin-like antibiotics, such as Amocrin, had been the preferred choice, but in recent years, due to an increase in the resistance of some strains to penicillin, moderately resistant strains could be selected for headactin, such as fentanyl, and highly resistant strains might require the use of Vancin or Lineazine. Infection of haemophilus influenzae can be found in ammonia sielin/shubattan, or
Two, three generations of sepsis, e.g., scrawl, pine. Cartamourella is sensitive to the Amosicillin/Clavic acid, and to the type of sapilin.
Hospitals have access to the more complex strains of Pneumonia (HAP) pathogens, most of which are gerranes, e.g., copper-false cystasy, intestinal bacteria (e.g., coli, crebera pneumonia) and yellow grapes. Bronze green cystasy infection is optional to anti-false cystasy β-neamide (e.g., thalamus, capone/shubartan, Zolacillin/Talbathan) combined amino-slucose (e.g., Amika) or quinone (e.g., ring prosa). Bacteria infections in intestinal bacterium are based on drug-sensitivity selections for head bacterium, carbon pyroacne, etc. Methoxysilin-negative gluccus (MRSA) infection requires the use of Vungucin, Linamazine or sub-kolanin.
II. Consideration of individual patients
Individual factors, such as the age of the patient, the underlying illness and the state of liver and kidney function, have an important impact on drug selection. Older patients suffer from reduced liver and kidney function and reduced drug metabolism and excretion, with careful dose adjustment and monitoring of adverse effects. For example, amino-cluenium antibiotics are renal toxic and should be used with caution among older patients and, if necessary, closely monitor the kidney function.
For people with underlying diseases, such as those with chronic obstructive pulmonary disease (COPD) who are susceptible to co-infection with copper green fake cystasy, there is a preventive choice of anti-false cystasy drugs; for diabetics, there is a high risk of yellow sepsis infection and it is not easy to control it; in the choice of antibacterial drugs, the coverage of the fungi is considered and the synergy of blood sugar control for the treatment of infection is emphasized.
The use of drugs for children with disabilities takes into account the effects of drugs on growth and development. Drugs such as quinone can affect the cartilage development of children and are generally not used for children under 18. The Great Encycloester Antibiotic, such as Archicin, is more effective and safe for children with pneumonia and is often selected.
Reference to local bacterial resistance
There are differences in the bacterial resistance spectrum between regions. Medical institutions should regularly monitor resistance to common pathogens in the region as an important reference for clinical use. For example, in some regions where pneumocococcal is highly resistant to cytone-based antibiotics, individual use of cytone-based drugs in the treatment of CAP needs to be careful to combine other drugs or to replace them with other suitable antibacterial drugs. Knowledge of local bacterial resistance helps to avoid the use of drugs with high resistance rates and increases the success rate of initial treatment.
IV. DRUG SECURITY AND DISAPPEARANCES
The efficacy and safety of the drug must be weighed in the choice of antibacterial drugs. Some antibacterial drugs may have severe adverse effects, such as chlorcin, which can lead to bone marrow inhibition, and are used with rigorous adaptive certificates and close monitoring of blood routines. Although β-neamide antibiotics are relatively safe, some patients may have allergic reactions, with detailed requests for allergies prior to the use of the drug, as well as allergies, such as pedding tests.
In addition, the interaction between drugs is given greater attention in the context of joint use. In the case of co-use of head enzyme and amino sugar, which may increase the risk of renal toxicity, the kidney function needs to be closely monitored and dose adjusted.
In sum, the choice of anti-bacterial drugs for pneumonia treatment is a complex process that combines multiple factors. Clinicians need to develop a rational and effective antibacterial treatment programme to increase the rate of pneumonia, reduce the incidence of complications and promote early recovery, taking into account local bacterial resistance information, taking into account the safety of the drug and adverse reactions, in order to determine the exact type of pathogen.
